OS Therapies Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OSTX research report →
Price Chart
About the company
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
- CEO
- Paul A. Romness
- IPO
- 2024
- Employees
- 5
- HQ
- Grasonville, MD, US
Get TickerSpark's AI analysis on OSTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $42.00M
- P/E
- -0.74
- Fwd P/E
- 13.38
- PEG
- 0.01
- P/S
- 0.00
- P/B
- -2.48
- EV/EBITDA
- -1.04
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 1.47%
- ROIC
- 287.18%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-363,085-12960.6%
- Op Income
- $-28,705,701
- Net Income
- $-28,753,844-223.7%
- EPS
- $-0.98-88.5%
- OCF Growth
- -95.5%
- FCF Growth
- -95.5%
- 52W High
- $2.25
- 52W Low
- $0.58
- 50D MA
- $1.35
- 200D MA
- $1.53
- Beta
- -0.64
- RSI (14)
- 35
- Avg Volume
- 720.93K
No earnings-call transcripts are available for OSTX yet.
- Free Float
- 57.0%
- Shares Outstanding
- 52.30M
- Float Shares
- 29.83M
of shares held by institutions
31 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 777.65K | 0 |
| Vanguard Group Inc | 540.42K | ▲ 352.16K |
| Cm Management, LLC | 400.00K | 0 |
| Geode Capital Management, LLC | 370.95K | ▲ 69.15K |
| Blackrock, Inc. | 245.15K | ▲ 2.67K |
| Vanguard Fiduciary Trust Co | 222.77K | ▲ 48.64K |
| State Street Corp | 155.80K | ▲ 35.70K |
| Marshall Wace, Llp | 100.64K | ▲ 100.64K |
| Hightower Advisors, LLC | 91.65K | ▲ 6.10K |
| Northern Trust Corp | 70.82K | ▲ 4.76K |
| Beacon Pointe Advisors, LLC | 62.51K | 0 |
| Bridgeway Capital Management, LLC | 45.00K | ▲ 20.00K |
Held by 23 ETFs
Biggest fund positions in OSTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | Clem Kerry M | other | 700,000 |
| Nov 10, 26 | Clem Kerry M | other | 200,000 |
| Nov 10, 26 | Francis Knuettel II | other | 750,000 |
| Nov 10, 26 | Francis Knuettel II | other | 250,000 |
| Oct 22, 26 | PETIT ROBERT | other | 200,000 |
| Oct 22, 26 | McKean-Dieser Avril Suzette | other | 300,000 |
| Oct 22, 26 | Romness Paul A. | other | 900,000 |
| Oct 22, 26 | Search Theodore F. | other | 300,000 |
| Oct 22, 26 | Ciccio John | other | 300,000 |
| Oct 22, 26 | Jarry Olivier Roger | other | 300,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OSTX coverage
Recent articles, reports, and earnings notes.
No research on OSTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OSTX report →OS Therapies Announces Shelving of U.S. FDA Commissioner's National Priority Voucher Has No Impact on the Company
newsfilecorp.com · Nov 13
OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
newsfilecorp.com · Nov 10
OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial
newsfilecorp.com · Nov 5
OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million
newsfilecorp.com · Oct 19
Rubenstein Public Relations Named Agency of Record for OS Therapies
globenewswire.com · Oct 8
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
newsfilecorp.com · Oct 7
OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment
benzinga.com · Oct 6
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
newsfilecorp.com · Oct 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.